deltatrials
Completed PHASE2 NCT00557037

A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer

Sponsor: MEI Pharma, Inc.

Interventions Phenoxodiol
Updated 5 times since 2017 Last updated: Apr 6, 2010 Started: Nov 30, 2007 Completion: Nov 30, 2009

This PHASE2 trial investigates Prostate Cancer and is currently completed. MEI Pharma, Inc. leads this study, which shows 5 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 19 months · monthly snapshotCompleted

Change History

5 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • MEI Pharma, Inc.
Data source: MEI Pharma, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .